Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

Detalhes bibliográficos
Autor(a) principal: Carneiro Neto, Jose Abraão
Data de Publicação: 2018
Outros Autores: Santos, Silvane Braga, Orge, Gloria Orge, Tanajura, Davi, Passos, Lucia, Oliveira, Cassius José, Andrade, Rosana, Melo, Cláudio Galeno de, Barroso, Ubirajara, Carvalho Filho, Edgar Marcelino
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/27131
Resumo: Universidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
id CRUZ_204bd69fb711281827154696a49c5345
oai_identifier_str oai:www.arca.fiocruz.br:icict/27131
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Carneiro Neto, Jose AbraãoSantos, Silvane BragaOrge, Gloria OrgeTanajura, DaviPassos, LuciaOliveira, Cassius JoséAndrade, RosanaMelo, Cláudio Galeno deBarroso, UbirajaraCarvalho Filho, Edgar Marcelino2018-06-26T17:55:09Z2018-06-26T17:55:09Z2018CARNEIRO NETO, J. A. et al. Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder. Brazilian Journal of Infectious Diseases, v. 22, n. 2, p. 79–84, 2018.1413-8670https://www.arca.fiocruz.br/handle/icict/2713110.1016/j.bjid.2017.10.009engElsevierBexiga hiperativaToxina onabotulínicaHTLV-1Overactive bladderOnabotulinum toxinHTLV-1Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladderinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleUniversidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / Universidade Estadual de Feira de Santana. Feira de Santana, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Urologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Urologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Urologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Pesquisa Clínica. Salvador, BA, Brasil / Instituto Nacional de Ciência e Tecnologia de Doenc¸as Tropicais. Salvador, BA, BrasilTo evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL). Methods: Case series with 10 patients with overactive bladder refractory to conservativetreatment with anticholinergic or physical therapy. They received 200Ui of onabotulinum-toxin type A intravesically and were evaluated by overactive bladder symptoms score(OABSS) and King’s Health Questionnaire.Results: The mean (SD) of the age was 52 + 14.5 years and 60% were female. All of them hadconfirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. Themedian and range of the OABSS was 13 (12–15) before therapy and decreased to 1.0 (0–12)on day 30 and to 03 (0–14) on day 90 (p < 0.0001). There was a significant improvement in 8 ofthe 9 domains of the King’s Health Questionnaire after the intervention. Hematuria, urinaryretention and urinary infection were the complications observed in 3 out of 10 patients. Themean time to request retreatment was 465 days.Conclusion: Onabotulinum toxin type A intravesically reduced the OABSS with last long effectand improved the quality of life of HTLV-1 infected patients with severe overactive bladder.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/27131/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALCarneiro Neto JA Onabotulinumtoxin type A improves lower ......pdfCarneiro Neto JA Onabotulinumtoxin type A improves lower ......pdfapplication/pdf706114https://www.arca.fiocruz.br/bitstream/icict/27131/2/Carneiro%20Neto%20JA%20Onabotulinumtoxin%20type%20A%20improves%20lower%20......pdfb9212b392b344bad0398cdf571f61ce6MD52TEXTCarneiro Neto JA Onabotulinumtoxin type A improves lower ......pdf.txtCarneiro Neto JA Onabotulinumtoxin type A improves lower ......pdf.txtExtracted texttext/plain25370https://www.arca.fiocruz.br/bitstream/icict/27131/3/Carneiro%20Neto%20JA%20Onabotulinumtoxin%20type%20A%20improves%20lower%20......pdf.txtbe8c03a9af116c65be4ed70dbe63bf7dMD53icict/271312023-03-15 14:34:13.355oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:13Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
title Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
spellingShingle Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
Carneiro Neto, Jose Abraão
Bexiga hiperativa
Toxina onabotulínica
HTLV-1
Overactive bladder
Onabotulinum toxin
HTLV-1
title_short Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
title_full Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
title_fullStr Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
title_full_unstemmed Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
title_sort Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
author Carneiro Neto, Jose Abraão
author_facet Carneiro Neto, Jose Abraão
Santos, Silvane Braga
Orge, Gloria Orge
Tanajura, Davi
Passos, Lucia
Oliveira, Cassius José
Andrade, Rosana
Melo, Cláudio Galeno de
Barroso, Ubirajara
Carvalho Filho, Edgar Marcelino
author_role author
author2 Santos, Silvane Braga
Orge, Gloria Orge
Tanajura, Davi
Passos, Lucia
Oliveira, Cassius José
Andrade, Rosana
Melo, Cláudio Galeno de
Barroso, Ubirajara
Carvalho Filho, Edgar Marcelino
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Carneiro Neto, Jose Abraão
Santos, Silvane Braga
Orge, Gloria Orge
Tanajura, Davi
Passos, Lucia
Oliveira, Cassius José
Andrade, Rosana
Melo, Cláudio Galeno de
Barroso, Ubirajara
Carvalho Filho, Edgar Marcelino
dc.subject.other.pt_BR.fl_str_mv Bexiga hiperativa
Toxina onabotulínica
HTLV-1
topic Bexiga hiperativa
Toxina onabotulínica
HTLV-1
Overactive bladder
Onabotulinum toxin
HTLV-1
dc.subject.en.pt_BR.fl_str_mv Overactive bladder
Onabotulinum toxin
HTLV-1
description Universidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
publishDate 2018
dc.date.accessioned.fl_str_mv 2018-06-26T17:55:09Z
dc.date.available.fl_str_mv 2018-06-26T17:55:09Z
dc.date.issued.fl_str_mv 2018
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv CARNEIRO NETO, J. A. et al. Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder. Brazilian Journal of Infectious Diseases, v. 22, n. 2, p. 79–84, 2018.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/27131
dc.identifier.issn.pt_BR.fl_str_mv 1413-8670
dc.identifier.doi.none.fl_str_mv 10.1016/j.bjid.2017.10.009
identifier_str_mv CARNEIRO NETO, J. A. et al. Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder. Brazilian Journal of Infectious Diseases, v. 22, n. 2, p. 79–84, 2018.
1413-8670
10.1016/j.bjid.2017.10.009
url https://www.arca.fiocruz.br/handle/icict/27131
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/27131/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/27131/2/Carneiro%20Neto%20JA%20Onabotulinumtoxin%20type%20A%20improves%20lower%20......pdf
https://www.arca.fiocruz.br/bitstream/icict/27131/3/Carneiro%20Neto%20JA%20Onabotulinumtoxin%20type%20A%20improves%20lower%20......pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
b9212b392b344bad0398cdf571f61ce6
be8c03a9af116c65be4ed70dbe63bf7d
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009100046336000

Registros relacionados